WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H123933
CAS#: 1092788-87-8
Description: CpCDPK1/TgCDPK1-IN-3 (Compound 20) is a CpCDPK1 and TgCDPK1 inhibitor
Hodoodo Cat#: H123933
Name: CpCDPK1/TgCDPK1-IN-3
CAS#: 1092788-87-8
Chemical Formula: C17H18N6
Exact Mass: 306.16
Molecular Weight: 306.370
Elemental Analysis: C, 66.65; H, 5.92; N, 27.43
Synonym: CpCDPK1/TgCDPK1-IN-3; Compound 20; CpCDPK1; TgCDPK1
IUPAC/Chemical Name: 1-isopropyl-3-(1-methyl-1H-indol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
InChi Key: SPUWUOGLPPVXCW-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H18N6/c1-10(2)23-17-14(16(18)19-9-20-17)15(21-23)12-4-5-13-11(8-12)6-7-22(13)3/h4-10H,1-3H3,(H2,18,19,20)
SMILES Code: NC1=C2C(N(C(C)C)N=C2C3=CC4=C(N(C)C=C4)C=C3)=NC=N1
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 306.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Shu F, Li Y, Chu W, Chen X, Zhang Z, Guo Y, Feng Y, Xiao L, Li N.
Characterization of Calcium-Dependent Protein Kinase 2A, a Potential Drug Target
Against Cryptosporidiosis. Front Microbiol. 2022 Apr 25;13:883674. doi:
10.3389/fmicb.2022.883674. PMID: 35558125; PMCID: PMC9090282.
2: Artz JD, Wernimont AK, Allali-Hassani A, Zhao Y, Amani M, Lin YH, Senisterra
G, Wasney GA, Fedorov O, King O, Roos A, Lunin VV, Qiu W, Finerty P Jr,
Hutchinson A, Chau I, von Delft F, MacKenzie F, Lew J, Kozieradzki I, Vedadi M,
Schapira M, Zhang C, Shokat K, Heightman T, Hui R. The Cryptosporidium parvum
kinome. BMC Genomics. 2011 Sep 30;12:478. doi: 10.1186/1471-2164-12-478. PMID:
21962082; PMCID: PMC3227725.
3: Hulverson MA, Vinayak S, Choi R, Schaefer DA, Castellanos-Gonzalez A,
Vidadala RSR, Brooks CF, Herbert GT, Betzer DP, Whitman GR, Sparks HN, Arnold
SLM, Rivas KL, Barrett LK, White AC Jr, Maly DJ, Riggs MW, Striepen B, Van
Voorhis WC, Ojo KK. Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. J
Infect Dis. 2017 Apr 15;215(8):1275-1284. doi: 10.1093/infdis/jix120. Erratum
in: J Infect Dis. 2018 Jan 4;217(2):340. PMID: 28329187; PMCID: PMC5853794.
4: Su J, Shen Y, Li N, Li Y, Zhang Z, Xiao L, Guo Y, Feng Y. Comparative
Characterization of CpCDPK1 and CpCDPK9, Two Potential Drug Targets Against
Cryptosporidiosis. Microorganisms. 2022 Feb 1;10(2):333. doi:
10.3390/microorganisms10020333. PMID: 35208789; PMCID: PMC8875172.